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Studies which aim at mapping genes contributing to the development of asthma and atopy demand that hundreds 
of patients and their family members be assessed. In Finland, the Social Insurance Institution (SII) grants substantial 
reimbursement for medication to all patients who meet diagnostic criteria of asthma, which include a history of 
asthmatic symptoms and a measured reversibility of bronchial obstruction. To recruit a large number of asthma 
patients efficiently in a short period of time, we took advantage of the national reimbursement procedure and 
retrospectively collective data on patients’ medical history and lung function test results at the time of diagnosis. 
First, we wanted to investigate if the reimbursements could be regarded as objective verification for self-reported 
asthma. Altogether 335 adult self-reported asthma patients were evaluated, 87% of them were verified as having 
chronic asthma. Reimbursement for medication showed a sensitivity of 95% and a specificity of 76% for verified 
asthma. 
Second, we were interested to see if self-reported nasal allergic symptoms or self-reported physician diagnosed 
allergic rhinitis were sensitive and specific measures of allergy. The self-reported allergic nasal symptoms had a poor 
specificity (31% in the proband group and 59% in the family members group) when compared to the allergy 
screening test (Phadiatopa). 
The best verification for self-reported asthma was achieved by combining the information on self-reported disease, 
granted reimbursement by the SII and the medical records. For allergies, the specificity of self-reporting was far too 
low to be used alone, and a positive allergy screening test together with relevant symptoms was chosen as a marker 
of allergy. 
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Introduction 
The mode of inheritance and the magnitude of a genetic 
effect compared to environmental factors in the develop- 
ment of asthma and other atopic diseases have been tradi- 
tionally studied in families and in twins. In these large, 
often population-based epidemiological studies which 
include up to thousands of study subjects, the diagnosis of 
asthma is usually based on patients’ self-reporting of the 
disease (1). Such questionnaire-based studies have been 
criticized for diagnostic inaccuracy. Lately a more specific 
question on physician-diagnosed asthma or allergic rhinitis 
has been used to avoid this problem (2,3). However, at a 
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population level, atopic diseases may still be misdiagnosed 
and false-negative cases especially may cause uncertainty in 
the epidemiology of atopic diseases (4). 
Genetic studies, which aim to identify susceptibility loci 
for multifactorial diseases such as asthma, also require a 
large number of study families (5). The expenses incurred in 
a careful clinical examination which include or exclude 
asthma in several hundreds of subjects under study are 
high. As in complex diseases in general, the severity and the 
clinical findings of the disease vary between different 
patients and also individually during a patient’s lifetime. At 
the same time, the diagnosis of asthma is still predomi- 
nantly based on a characteristic pattern of symptoms and a 
measurable reversible airway obstruction and/or bronchial 
hyperreactivity (BHR) (6). However, both the sensitivity of 
different lung function tests and the predictive value of any 
positive test have been shown to be generally low (7) and 
the repeatability of quantitative traits associated to asthma, 
such as BHR, is low (8). Inflammation in a bronchial 
biopsy specimen supports the diagnosis, but does not have 
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TABLE 1. Diagnostic criteria for reversible airway obstruction and hyperreactivity 
Improvement of FEV,* after &agonist or anti-inflammatory therapy 2 15% and 0.20 1 
Improvement of PEFt after &agonist 215% and 50lmin~’ 
Improvement of PEF baseline during anti-inflammatory therapy 2 20% and 50 1 min - i 
Diurnal variation of PEF 2 20% and 50 1 min - i 
Decrease of FEV, in exercise test 2 15% and 0.15 1 
Decrease of PEF in exercise test 2 15% and 50 1 min - ’ 
Decrease of FEV, in histamine or methacholine challenge% 2 15% and 0.20 1 
Decrease of PEF in histamine or methacholine challenge 215% and 50lmin’ 
*FEV,: forced expiratory volume in 1 s. Used spirometers: Vitalograph (Vitalograph Ltd, England), 
Jaeger (Erich GmbH, Germany) (15,16). TPEF: peak expiratory flow. Used peak flow meters: 
Wright, Mini-Wright (Clement Clarke International Ltd, England), Spira (Spira Ltd, Finland). 
$Used methods of histamine and methacholine challenge (cumulative doses of histamine from 
0.025 mg to 2,125 mg and of methacholine from 0.0075 mg to 4.0 mg): (17-19). 
any pathognomonic features compared to other character- 
istics of allergic inflammation (9). Because of a strong 
association between asthma and atopy, allergy screening is 
often included in the diagnostic procedure. The usefulness 
of inflammation markers in sputum is under investigation. 
Asthma-like symptoms especially among the first degree 
relatives of asthma patients are common (2,lO). Verification 
of the affection status of these family members in a single 
cross-sectional time point can be extremely difficult. On the 
other hand, an accurate diagnosis is considered to be crucial 
in monogenic diseases where gene mapping and positional 
cloning have identified disease causing gene defects (11). 
For the complex trait of asthma, it is not known whether a 
certain clinical subphenotype or a certain quantitative trait 
associated with asthma (serum IgE level or BHR) can better 
predict homogeneity in the molecular mechanisms of the 
disease (12,13). 
We recruited families for genetic studies of asthma in a 
province of Finland, hoping to take advantage of the 
genetic features of the Finnish population (5,ll). In 
Finland, the Social Insurance Institution (SII) grants a 
substantial reimbursement for asthma medication to all 
patients who meet diagnostic criteria such as asthmatic 
symptoms and reversible airway obstruction measured by 
spirometry or peak expiratory flow and/or positive hista- 
mine or methacholine challenge test (Table 1). This pro- 
cedure assures that especially patients who need regular 
medication are carefully diagnosed, including basic lung 
function testing before medication is started. The grounds 
for asthma diagnosis are nationally uniform and based on 
the recommendation of American Thoracic Society (6). In 
our study other aspects of the study design also favour the 
uniformity of diagnoses: the probands have been recruited 
from a geographically small region only and represent 
about 8% of the asthma patients of the province. Most of 
the diagnoses have been made in a single clinic for pulmon- 
ary medicine which has employed only few physicians over 
the years. In the year 1994, the proportion of people 
entitled to reimbursed anti-asthmatic medication was 3.4% 
in Kainuu and 2.8% in the whole country (14). 
This study was designed to answer the following ques- 
tions: could self-reported asthma be verified by the granted 
reimbursement by the SII and could self-reported allergic 
nasal symptoms or self-reported physician diagnosed 
allergic rhinitis be used alone as markers of airway allergy? 
To answer these questions, we reviewed the hospital files 
retrospectively to verify the diagnostic criteria for asthma 
and compared all this information with the self-reported 
data. In order to test the applicability of questions ‘Have 
you ever been diagnosed with allergic rhinitis by a physi- 
cian? and ‘Have you ever suffered from allergic nasal 
symptoms?‘, the responses of participants were compared 
with our allergy blood screening results. 
Materials and Methods 
STUDY POPULATION 
Study families were recruited through local newspapers 
and radio stations in Central Eastern Finland (Kainuu 
Province) during November 1994. The study area consists 
of one small town (36 859 inhabitants) and its rural sur- 
roundings (altogether 9.5 814 inhabitants). The area belongs 
to a continental subarctic climatic region with cold and 
snowy winter and cool and short summer. The selection 
criteria for a proband were: self-reported asthma diagnosed 
by a physician, the parents and/or grandparents born 
in Kainuu and the nuclear family willing to participate 
(proband - spouse - at least one child, or proband - 
mother - father, or proband ~ one of the parents - at least 
one sibling) [Fig. l(c)]. Additional affected family members 
(uncles, aunts, grandparents, cousins, further siblings) were 
included when available. The sample set was formed of 255 
nuclear families including 54 large pedigrees with multiple 
affected. All participants signed an informed consent where 
they gave permission to use their blood samples for a 
scientific study. They were also asked in which hospitals 
they had been diagnosed and treated and to give permission 
for their hospital files concerning asthma and allergy to be 
studied. The National Board of Health confirmed the 
permission to access these patients’ medical records. The 
study was approved by the ethical committees of the 
Department of Medical Genetics, University of Helsinki 
and the Kainuu Central Hospital. 
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(b) Probands contact the research group 
(c) Entry criteria for probands’ participation 
-self-reported asthma diagnosed by a physician 
-nuclear family willing to participate 
(d) Proband 
-informed consent 
-questionnaire and physician’s 
interview 
-blood sample 
(e) Family members 
-informed consent 
-questionnaire 
-blood sample 
~~~~ 
-verification of self-reported 
FIG. 1. Recruitment of the study population 
QUESTIONNAIRE 
Both the probands and their family members donated their 
blood samples and filled out a health questionnaire at the 
same session [Fig. l(d),(e)]. During a brief interview of the 
probands, the questionnaire was clarified and the written 
answers were discussed with a physician. The questions 
concerning allergies, smoking habits and other diseases 
were identical for probands and family members whereas 
the questions concerning respiratory symptoms were more 
detailed for the self-reported asthma patients. 
MEDICAL RECORDS 
On the basis of self-reported asthma, the medical records of 
probands were then reviewed separately by two pulmonary 
physicians [Fig. l(f)]. Descriptive remarks of the clinical 
condition and lung function test results were collected in a 
standardized form. The reversibility of airway obstruction 
and BHR were evaluated. Diagnostic results were consid- 
ered, e.g. improvement by at least 15% of forced expiratory 
volume in 1 s (FEV,) with &-agonist or decrease of FEV, 
in histamine or methacholine challenge by at least 1.5% 
(Table 1). Patients whose lung function tests had remained 
non-diagnostic or were insufficiently carried out or docu- 
mented at the time of diagnosis were followed through 
hospital records to obtain objective evidence either for or 
against asthma diagnosis. At the same time, other diseases 
were excluded as a possible cause for the patient’s dysp- 
noea, such as respiratory insufficiency with a history of 
pulmonary tuberculosis. 
TOTAL SERUM IGE AND SPECIFIC IGE 
ANTIBODIES 
Probands with self-reported asthma (~~~335) represented an 
adult population (mean age of 45 years, range from 16 to 83 
years) with a dominance of women (68%). Two pulmonary 
physicians reviewed and merged all available data from 
medical records and questionnaires filled in by the partici- 
pants. Based on those data the patients were divided into 
six diagnostic categories (Table 2). In 239 (71%) of the 
patients, self-reported asthma was confirmed based both on 
medical history and diagnostic lung function tests showing 
either reversible airway obstruction or BHR or both (Table 
3). The group of probable asthma (n = 54, 16%) included all 
patients whose medical records revealed similar and recur- 
rent symptoms of asthma as in the group of confirmed 
asthma, but as regards the documentation of lung function 
tests, these two groups differed. In the latter group, the tests 
were either insufficiently done or the results were not 
diagnostic according to our criteria (Table 1). Twenty of 
these patients had developed asthma in young adulthood 
(Table 3). However, both groups represented patients 
who had been regularly followed up by a physician and 
who had used regular anti-inflammatory medication 
for 5 years on average. Both groups also reported a 
constant need for medication and a clinical response 
to medication shown as a relief of asthma symptoms. 
Ninety-six per cent of the probands in the group with 
confirmed asthma had medication costs reimbursed by 
SII, while the corresponding number for the group with 
probable asthma was 89%. 
Serum samples were stored at - 70°C and analysed in one In the group with possible asthma (n= 14), some asthma 
batch in the same laboratory. The following parameters symptoms and reversible airway obstruction/BHR were 
were measured: an allergy screening test (Phadiatop CAP found, but during the follow-up period of 8 yr (on average), 
FEIA, Kabi Pharmacia, Sweden) with birch, mugwort, 
timothy, horse, cat, dog, house dust mite (Derrnatopha- 
goidespteronyssinus), and Cladosporium herbarum mould. If 
the allergy screening was positive (10.3 kU 1 - ‘), the levels 
of specific IgE antibodies were measured. The total serum 
IgE (Diagnostics CAP FEIA, Kabi Pharmacia, Sweden) 
was also measured. Among the Finns, the panel of eight 
aeroallergens listed above include the most commonly 
identified allergens (20) and specific IgE antibodies 
measured in serum are comparable to the results of skin- 
prick tests (21). The allergy screening test, as an objective 
indicator of allergy, was compared to the self-reported 
allergic nasal symptoms and self-reported physician 
diagnosed allergic rhinitis. 
STATISTICAL ANALYSIS 
All information obtained from the questionnaires, medical 
records and allergy screening tests were stored and analysed 
using Excel (Microsoft). The chi-squared test was applied in 
comparisons of the size of two different groups, and the 
Student’s t-test in comparisons between the average values 
of two different groups. 
Results 
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TABLE 2. Classification of patients with self-reported asthma according to their entitled 
reimbursement for medication (n= 335) 
Reimbursement for medication 
Diagnosis* 
Yes 
(n=287) 
Total 
(n=335) 
Confirmed asthma 
Probable asthma 
Possible asthma 
Chronic obstructive pulmonary disease 
Respiratory insufficiency 
with history of pulmonary tuberculosis 
with history of pulmonary fibrosis 
with history of pulmonary sarcoidosis 
Cardiac insufficiency 
with history of severe heart disease 
Insufficient data for classification 
229 10 i 
48 6 
0 14 
7 5 
2 
0 
0 
0 
1 
!39 
54 
14 
12 
3 
1 
1 
1 
10 
*Classification based on review of medical records. 
TABLE 3. Medical history and documentation of lung function tests in four main diagnostic categories of self-reported asthma 
patients (n = 3 19) 
Medical history 
Confirmed Probable 
asthma asthma 
(n=239) (n=54) 
Possible 
asthma 
(n=14) 
Chronic obstructive 
pulmonary disease 
(n=12) 
Reimbursement of medication costs 
Average age at diagnosis (years) 
Average follow-up period (yr) 
Diagnosis made in childhood 
Current need for regular anti-inflammatory therapy 
Average duration of anti-inflammatory therapy (yr) 
Wheezing by auscultation 
Smoking regularly > 10 yr 
Lung function tests 
229 (96%) 48 (89%) 
38 24 
6.4 11.3 
11 (5%) 20 (37%) 
201 (84%) 30(56%) 
4.6 4.8 
164 (69%) 25 (46%) 
46 (19%) 8 (15%) 
n n 
0 (0%) 7 (58%) 
27 51 
7.8 6.4 
3 (21%) 0 (0%) 
1 (7%) 9 (75%) 
co.1 5.3 
4(29%) 6 (50%) 
0 (0%) 12 (100%) 
n n 
Spirometry 236 (99%) 28 (52%) 9 (64%) 8 (67%) 
PEF monitoring 211 (88%) 17 (31%) 9 (64%) 7 (58%) 
Exercise test 72 (30%) 12 (22%) 4 (29%) 2 (17%) 
Histamine or methacholine challenge test 180 (75%) 11 (20%) 8 (57%) 5 (42%) 
neither recurrent symptoms nor a need for medication had 
developed (Table 3). None of the individuals in this 
group had reimbursement for medication. The group with 
chronic obstructive pulmonary disease (COPD, n= 12) 
included all patients who had smoked for over 20 yr. 
The main component of their disease was irreversible 
obstruction of the airways developed at an average age of 
57 years, and seven individuals in this group had SII 
reimbursement for medication. Three patients had a history 
of lung tuberculosis causing respiratory insufficiency, two 
of the patients had a systemic disorder with pulmonary 
involvement, and one had a severe heart condition. All 
these patients had dyspnoea, but no clinical evidence of 
asthma, although two persons with a history of lung 
tuberculosis had developed a respiratory insufficiency with 
an obstructive component and thus were entitled to the 
reimbursement by SII. In 10 patients the medical records 
were insufficient or not available for classification. 
On the whole, reimbursement for medication showed a 
sensitivity of 95% (277/293) and a specificity of 76% (32/42) 
among the self-reported asthma patients when compared to 
our combined data of self-reported asthma and information 
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on medical records as a standard. Of all self-reported 
asthma patients, asthma was verified in 87% (293/335) and 
of those with granted reimbursement, asthma was verified 
in 97% (277/287) (Table 2). 
Twenty-seven per cent of the family members who had 
never been diagnosed as having asthma (n=403) reported 
symptoms of dyspnoea and/or wheezing, 37% reported 
recurrent airway infections, and 24% reported prolonged 
cough. Fifty-three family members (13%) reported the 
occasional use of anti-asthmatic medication at some point 
in their lives. 
SELF-REPORTED ALLERGIC RHINITIS 
Screening for IgE-mediated allergy was done for the most 
common aeroallergens in Finland (20). The allergy screen- 
ing test results (PhadiatopB) were used as the objective 
verification to calculate sensitivity, specificity and predictive 
values. The test results were compared to the participants’ 
responses to both of the questions on nasal allergic symp- 
toms and on physician diagnosed allergic rhinitis among the 
asthma patients and among their family members (Table 4). 
However, neither of the questions reached a high sensi- 
tivity, specificity or positive or negative predictive value. 
Among the self-reported asthma patients, 90% of the 
allergy screening positive, but also 69% of those screening 
negative, reported symptoms of allergic rhinitis. The 
corresponding figures among their family members were 
71% and 41%, respectively. Physician diagnosed allergic 
rhinitis showed a better specificity than self-reported 
allergic symptoms in both of the groups. Seventeen percent 
of the asthma patients and 18% of the family members 
did not answer the question of physician diagnosed 
allergic rhinitis. 
Clinically, the allergy screening positive and negative 
participants differed in age (mean 36 vs 50 years, RO.0001) 
and in smoking habits (current smokers 25% vs 14%, 
P<O.O05), whereas gender did not have a significant effect 
(males 45% vs 41%, respectively). As expected, allergy 
screening was more frequently positive among the asthma 
patients (41%) than among their family members (21%, 
WO.0001). Serum total IgE levels were significantly higher 
in the screening positive group (mean 390 kU 1-i) com- 
pared to the allergy screening negative group (mean 
66 kU 1~ ‘; P<O.OOOl). Among allergy screening positive 
individuals, 51% had specific IgE antibodies for timothy, 
51% for cat, 45% for dog, 43% for house dust mite, 36% for 
birch, 18% for mugwort, and 10% for the mould Cludospo- 
uium herbavum. The spectrum of allergy antibodies among 
the asthma patients did not differ from that found among 
the family members, but the screening positive asthma 
patients had more frequently two or more specific anti- 
bodies elevated (72%) compared to their non-asthmatic 
family members (49%, P<O.OOl). 
Discussion 
Our study showed that asthma is a well-known disorder 
among Finns, and that the nationwide criteria of chronic 
diseases employed by the SII can offer valid information on 
diagnostic findings. Granted reimbursement for medication 
showed a sensitivity of 95% and a specificity of 76% among 
the probands when compared to our combined data used as 
a reference. Of those with granted reimbursement for 
medication, 97% were verified as having asthma. Of all the 
self-reported asthma patients asthma could be verified in 
87%. These figures show that the reimbursement procedure 
is a good predictor for asthma, but not all true asthmatics 
had reimbursement. Differences in the documentation of 
lung function tests can be explained by the fact that for 19 
patients in the group with probable asthma the diagnosis of 
asthma was made long ago (>14 years) compared to the 
patients in other diagnostic groups. Thus, we may have 
failed in some cases to trace the actual test results. For 20 
patients the diagnosis was made already in childhood and 
relied on the clinical picture alone. These two groups of 
patients have been included in our further studies on the 
genetics of asthma (22). 
The main confounding groups of patients were long-term 
smokers (4%) and patients with mild asthma-like symptoms 
that were not diagnosed as chronic asthma at the time of 
the study (4%). In both conditions, the clinical picture of 
the disease resembles that of asthma and medication is 
often indicated. It is possible that the same genetic factors 
predisposing to asthma also have a role in the development 
of COPD, and that the responders with mild respiratory 
distress will later develop chronic asthma. However, these 
patients, like the responders with some other pulmonary or 
heart disease (2%) were excluded to avoid heterogeneity in 
the aetiology of airway obstruction. For 3% of patients we 
were not able to trace any medical records on asthma and 
they were also excluded. 
The results concerning allergic rhinitis were more contro- 
versial. Ninety per cent of the allergy screening test positive 
asthma patients and 71% of the allergy screening test 
positive family members had self-reported allergic rhinitis, 
but many individuals with a negative allergy screening test 
(69% and 41%, respectively) also reported symptoms. 
Among both the asthma patients and their family members, 
the question of physician-diagnosed allergic rhinitis showed 
a higher specificity, but a lower sensitivity than self- 
reported allergic nasal symptoms (Table 4). Chronic rhini- 
tis, either allergic or vaso-motoric in origin, is common 
especially among asthmatics (23). The difference diagnosis 
between these subtypes depends on whether the symptoms 
are associated with allergen exposure and a specific IgE 
response. However, IgE mediated reactivity is known to 
diminish with age (24). The discordance between allergic 
symptoms and screening results was greater than previously 
published among Finnish adolescents (21). This might be 
explained by the difference in the age distribution and by 
the question designed to assess either ‘current allergies’ or 
‘allergies ever’ as in our study (21). Even though atopy is 
indisputably increasing in Finland as in other industrialized 
countries (25,26), the high number of allergy screening 
positive individuals among the young study subjects may 
partly be due to an age-dependent, strong IgE response. In 
addition to age, current smoking was shown to elevate IgE 
levels which can also act as a confounding factor in genetic 
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studies, In general, the Finns represent a population with 
a rather low prevalence of asthma and allergic rhinitis 
(27-29) compared to many other populations like the 
Australians or the New Zealanders (30,31). The occurrence 
of airway allergies or the spectrum of the allergies did not 
differ from those found in recent epidemiological studies in 
Finland (27) and Sweden (32). Based on all information, in 
our forthcoming genetic studies airway allergy is defined as 
either a positive allergy screening, or an elevated serum 
total IgE level (> 100 kU l- ‘) with accompanying allergic 
symptoms of the airways. 
Reviewing the medical records was time-consuming but 
could still be regarded as cost-effective in this population 
where the diagnostic criteria of asthma are uniform because 
of the SII reimbursement procedure. Except for the blood 
tests, there was no need for extra tests such as spirometrics 
or bronchial challenge tests that would have been inconven- 
ient for the participants and expensive to carry out. Lung 
function testing had already been done for the majority of 
the self-reported asthma patients: a spirometry had been 
done in 99% of the patients and a PEF monitoring in 88% 
of the group with confirmed asthma (Table 3). Also, if the 
lung function tests had been done now the findings would 
have probably been different from those done at the time of 
diagnosis for each patient, or less clear because of the given 
treatment with anti-inflammatory agents, both factors 
being likely to introduce further heterogeneity. 
Several family studies before ours have shown an 
increased incidence of asthma among first degree family 
members of asthma patients in comparison to general 
population (l,lO). In our study, 13% of the family members 
reported the use of anti-asthmatic medication at some point 
of their lives even though a specific diagnosis had never 
been made. By choosing not to do physical examinations 
among the family members, we have probably lost some 
affected family member pairs, but avoided false-positive 
affected pairs. Furthermore, not even the most careful 
clinical examination can predict the risk of morbidity 
among the unaffected. Misclassification of asthma patients 
as controls tends to be conservative for statistical calcula- 
tions since group differences become diminished rather than 
exaggerated. Thus, any positive findings of significant dif- 
ferences are likely to be real. For genetic linkage disequi- 
librium studies in which the allele or haplotype frequencies 
among the affected are compared to the controls, unaffected 
spouses of the asthma patients represent optimal family- 
and population-based controls. The study of an isolated 
population may offer specific advantages for genetic studies 
because of reduced genetic heterogeneity (5,11,29). In 
addition, medical diagnostics tend to be more uniform in a 
regionally restricted population. We have taken advantage 
of these features and the standardized diagnostic pro- 
cedures for asthma in Finland. With objective verification 
for diagnoses of asthma and allergic rhinitis, the study group 
should be especially well suited for genetic studies (22). 
We conclude that self-reported diseases, such as asthma, 
can be used as a sampling method and by combining this 
with valid retrospective data on diagnostic findings it can be 
used as an efficient approach for large epidemiological or 
genetic studies. These principles might also be applicable in 
SELF-REPORTING AND GENE MAPPING 1287 
other populations with similar organization of asthma care. 
The general knowledge of allergic symptoms is not specific 
and thus self-reported allergies also need to be verified by 
objective measurements. 
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